A group of industry investors have announced the 100% acquisition of CorePharma in Middlesex, NJ from Impax Laboratories. 

The acquisition does include all equity, equipment, and facilities, but does not include any pending or approved Abbreviated New Drug Applications (ANDAs) or currently marketed products. 

Effective immediately upon closing of the deal, Arpit Patel has been appointed as the chief executive officer of CorePharma, and will also become a member of the Board of Directors.  Dr. Vithal Dhaduk, one of the original founders of CorePharma has been appointed as president and chairman of the Board of Directors.

“We are very excited to acquire CorePharma. The CorePharma team, under Impax ownership, has done a fantastic job at their Middlesex facility,” Patel said. “This was evident from their stellar regulatory compliance track record. We are looking forward to building upon their past successes and remain committed to being a trusted, reliable and respectable partner of choice for manufacturing high-quality generic and branded pharmaceuticals.”

CorePharma’s headquarters in Middlesex house two fully capable state-of-the-art manufacturing and packaging facilities totaling approximately 60,000 square feet. They are both FDA and DEA registered and have a wide range of capabilities in the Oral Solid Dosage space with the ability to manufacture and package over one billion dosage units per year.